Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
GlobeNewswire - Fri May 15, 7:05AM CDT
Collaboration Using Renishaw Plc's Convection-Enhanced Delivery Device Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas
Amarantus BioScience Holdings, Inc. - "MANF Begins its March Towards the Clinic"
ACCESSWIRE - Thu May 14, 12:35PM CDT
NEW YORK, NY / ACCESSWIRE / May 14, 2015 / Amarantus BioScience Holdings, Inc. (PINKSHEETS: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's Independent Director, Joseph Rubinfeld, PhD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
New Collaborations Lead to Advancements in Human Clinical Trials for Development of Clinical Grade Production for Therapeutic Product Candidates With Proprietary Technologies
PR Newswire - Thu May 14, 7:45AM CDT
Therapeutic treatment applications for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine and other rare orphan conditions search for new advancements through continued research and human clinical studies. Specialty Biotech companies in focus today are: Amarantus BioScience Holdings, Inc. (OTC: AMBS), Discovery Laboratories, Inc. (NASDAQ: DSCO), Fibrocell Science, Inc., (NASDAQ: FCSC), OPKO Health, Inc. (NYSE:OPK) and AbbVie Inc. (NYSE: ABBV).
OPK: 16.92 (+0.24), FCSC: 4.02 (+0.01), CTLT: 30.43 (+1.11), ABBV: 65.99 (+0.02), BMY: 67.64 (+0.19), DSCO: 0.96 (+0.04)
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
GlobeNewswire - Thu May 14, 7:05AM CDT
- Catalent to Utilize Proprietary GPEx Platform for Production of High Performance MANF Expressing Cell Line -
CTLT: 30.43 (+1.11)
Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.38 (+0.07), LPTN: 1.83 (+0.04), CNCE: 14.13 (-0.05), ATHX: 1.27 (-0.01), KPTI: 24.81 (-2.02), CUR: 1.70 (-0.04)
Amarantus receives NOA for patent covering lead product candidate
Seeking Alpha - at Seeking Alpha - Wed May 13, 3:18PM CDT
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
GlobeNewswire - Wed May 13, 12:00PM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 11/713,156 entitled, "Pharmacological Treatment of Parkinson's Disease." Upon issuance, the patent will provide additional intellectual property protection for the Company's lead product candidate, eltoprazine. The allowed patent claims cover methods and compositions for the administration of eltoprazine for the alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.
Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
GlobeNewswire - Mon May 11, 7:35AM CDT
-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis-
Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire - Thu May 07, 10:15AM CDT
- Study conducted by leading researchers at University of Miami -
Amarantus wins USPTO's Notice of Allowance for patent application covering proprietary compositions of matter and methods for MANF
M2 - Wed May 06, 4:05AM CDT
Biotechnology company Amarantus BioScience Holdings (OtherOTC:AMBS) revealed on Tuesday that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US patent application entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof."
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
GlobeNewswire - Tue May 05, 7:05AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.
Latin America, Africa and Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019
M2 - Tue May 05, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/53vpq4/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Latin America, Africa and Middle East Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Latin America, Africa & The Middle East 6. Global Market Summary Companies Mentioned - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/53vpq4/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)
Asia Pacific Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015-2019
M2 - Tue May 05, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9wvdm/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Asia Pacific 6. Global Market Summary Companies Mentioned - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/v9wvdm/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)
North America Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015-2019
M2 - Tue May 05, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vlz7vv/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - North American Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Global Market Summary 7. The Future of the Clinical Laboratory Companies featured: Partial List - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/vlz7vv/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)
European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019
M2 - Tue May 05, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b6k9j8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Europe Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Europe 6. Global Market Summary 7. The Future of the Clinical Laboratory Companies Mentioned: Partial List - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/b6k9j8/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)
Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019
M2 - Tue May 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6l9drr/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 - Global Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Trends like: - Changing demographics - Emerging economies and global prosperity - Biotechnology advances in genetics - Pathogen evolution - Climate change - Globalization - Automation Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - Partial List of the 350 Companies Featured - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/6l9drr/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)
BUYINS.NET Updates Amarantus BioSciences (AMBS) SqueezeTrigger Report
M2 - Fri May 01, 6:47AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTC: AMBS) after releasing the latest short sale data through April 30, 2015. The total aggregate number of shares shorted since June 2011 is approximately 1.41 billion shares. Approximately 29.66% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.078. A short squeeze is expected to begin when AMBS is above its SqueezeTrigger Price.
Amarantus human growth factor tagged an Orphan Drug in Europe for retinal disease
Seeking Alpha - at Seeking Alpha - Wed Apr 29, 8:37AM CDT
Orphan Drug Designations Lead to New Therapeutic Breakthroughs for Rare Disorders and Diseases
PR Newswire - Wed Apr 29, 7:45AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA & EU to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Biotech Companies in focus today are: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Catalyst Pharmaceutical Partners' (NASDAQ: CPRX), Biogen Inc. (NASDAQ: BIIB), Hemispherx Biopharma, Inc. (NYSE: HEB) and Biocept, Inc. (NASDAQ: BIOC).
BIIB: 391.24 (-3.11), CPRX: 3.32 (-0.02), HEB: 0.25 (unch), BIOC: 2.91 (+0.15)
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
GlobeNewswire - Wed Apr 29, 6:05AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The Company previously announced in December of 2014 that it also received orphan drug designation for MANF for the treatment of RP from the U.S. Food and Drug Administration (FDA).